ABSTRACT

The association between diabetes mellitus (DM) and hypothyroidism in cardiovascular disease (CVD) is well established. Both are associated with significant adverse impacts on patients undergoing percutaneous coronary interventions (PCI). DM is an independent predictor of adverse outcomes after drug-eluting stent (DES) implantation. Despite reasonable glycemic control in the peri-procedural period, DM is associated with worse clinical outcomes than non-diabetic patients. Hypothyroidism leads to higher cardiovascular comorbidities and is associated with an increased incidence of major adverse cardiac and cerebrovascular events (MACCE) than euthyroidism in PCI patients. Low T3 syndrome has also been associated with adverse outcomes in PCI patients. Diagnosis and optimal management of hypothyroidism may improve outcomes in CAD patients undergoing PCI. This review focus on the impact of T2DM and hypothyroidism in patients undergoing PCI. Keywords: Acute coronary syndrome, Coronary artery disease, Endocrine disorder, Revascularisation, Major adverse cardiac and cerebrovascular events
Publication date: 01/01/2023

https://ijbpas.com/pdf/2023/January/MS_IJBPAS_2023_6778.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.1.6778